BioCryst (BCRX) AI Stock Analysis

• Market Cap: $1.57B
• Dividend Yield: N/A
• Average Volume (3M): 4.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 45.38%
• EPS Growth: 92.85%
• Country: US
• Employees: 580
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 210,543,230
• 10 Day Avg. Volume: 4,370,675
• 30 Day Avg. Volume: 4,116,436
• PEG Ratio: 0.28
• Price to Book (P/B): -3.27
• Price to Sales (P/S): 3.45
• P/FCF Ratio: -29.25
• Enterprise Value/Market Cap: 1.36
• Enterprise Value/Revenue: 3.57
• Enterprise Value/Gross Profit: 3.66
• Enterprise Value/Ebitda: 25.50
• 1Y Price Target: $19.45
• Price Target Upside: 172.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): $619.06M

• Rating: 55 Neutral
• Price Target: $8.00 ▲(12.20% Upside)

BioCryst's overall stock score reflects a mix of strong strategic moves and significant financial challenges. The positive impact of recent corporate events and earnings call guidance is offset by weak financial performance and valuation metrics. The company's ability to address financial risks and capitalize on strategic initiatives will be crucial for future performance.

Positive Factors

FDA Approval for Pediatric HAE Drug

The FDA approval for a pediatric formulation of ORLADEYO expands BioCryst's market reach and strengthens its competitive position in the HAE treatment space, potentially driving long-term revenue growth.

Strategic Acquisition of Astria Therapeutics

Acquiring Astria Therapeutics is expected to bolster BioCryst's product pipeline and market position, providing strategic growth opportunities and enhancing its competitive edge in rare disease treatments.

Revenue Growth and Guidance

Strong revenue growth and increased guidance for ORLADEYO highlight BioCryst's successful market penetration and product adoption, supporting a positive long-term financial outlook.

Negative Factors

High Leverage and Negative Equity

High leverage and negative equity indicate financial instability, posing risks to BioCryst's long-term solvency and limiting its ability to invest in growth opportunities.

Cash Flow Challenges

Persistent cash flow challenges could hinder BioCryst's ability to fund operations and strategic initiatives, impacting its financial flexibility and long-term sustainability.

Profitability Issues

Ongoing profitability issues, as indicated by negative net margins, suggest difficulties in achieving sustainable earnings, potentially affecting BioCryst's long-term financial health.

BioCryst Business Overview & Revenue Model

Company Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

How the Company Makes Money

BioCryst generates revenue primarily through the sale of its approved products, particularly ORLADEYO, which is marketed directly to patients and healthcare providers. In addition to product sales, the company may also earn revenue from strategic partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships can involve upfront payments, milestone payments based on development progress, and royalties on future sales of products developed from these collaborations. The company’s focus on rare diseases often allows for premium pricing of its therapies, further enhancing its revenue potential.

BioCryst Financial Statement Overview

Summary

BioCryst is experiencing revenue growth but faces significant challenges in profitability and financial stability. The high leverage and negative equity position pose risks, while cash flow issues further complicate the financial outlook.

Income Statement

BioCryst has shown a positive revenue growth trend with a 7.59% increase in the TTM period. However, the company is still struggling with profitability, as indicated by a negative net profit margin of -1.46% and a low EBIT margin of 8.47%. The gross profit margin remains strong at 97.39%, suggesting efficient cost management, but the overall profitability metrics indicate challenges in achieving net income.

Balance Sheet

The balance sheet reflects a high level of leverage with a negative debt-to-equity ratio of -1.75, indicating significant financial risk. The company has negative stockholders' equity, which is concerning. Return on equity is positive at 1.93%, but this is due to the negative equity base rather than strong performance. The equity ratio is not favorable, indicating potential solvency issues.

Cash Flow

BioCryst's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow growth rate is negative at -137.36% for the TTM period, highlighting cash flow difficulties. However, the free cash flow to net income ratio is positive at 1.13, suggesting that cash flow generation relative to net income is somewhat stable, albeit from a negative base.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	599.82M	450.71M	331.41M	270.83M	157.17M	17.81M
Gross Profit	583.80M	438.23M	326.75M	264.23M	149.91M	16.14M
EBITDA	83.87M	12.81M	-116.33M	-143.85M	-121.74M	-167.56M
Net Income	-8.78M	-88.88M	-226.54M	-247.12M	-184.06M	-182.81M
Balance Sheet
Total Assets	446.42M	490.42M	516.96M	550.00M	588.15M	334.71M
Cash, Cash Equivalents and Short-Term Investments	212.87M	321.06M	388.99M	424.31M	507.60M	300.37M
Total Debt	683.11M	841.42M	825.15M	741.45M	593.24M	279.50M
Total Liabilities	834.31M	966.35M	972.49M	844.60M	695.14M	353.98M
Stockholders Equity	-387.89M	-475.93M	-455.53M	-294.60M	-106.99M	-19.26M
Cash Flow
Free Cash Flow	47.34M	-53.14M	-97.31M	-163.20M	-144.54M	-137.73M
Operating Cash Flow	49.68M	-52.02M	-95.14M	-161.85M	-142.16M	-137.22M
Investing Cash Flow	87.59M	52.59M	-131.50M	-128.24M	15.80M	-6.86M
Financing Cash Flow	-135.48M	-5.76M	32.48M	88.03M	359.67M	302.70M

BioCryst Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCRX, the sentiment is Negative. The current price of 7.13 is below the 20-day moving average (MA) of 7.34, below the 50-day MA of 7.17, and below the 200-day MA of 8.26, indicating a bearish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 43.34 is Neutral, neither overbought nor oversold. The STOCH value of 24.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCRX.

BioCryst Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	79 Outperform	$2.09B	28.14	20.65%	―	20.62%	―
VCEL	71 Outperform	$1.80B	151.16	4.52%	―	14.05%	241.86%
CDTX	60 Neutral	$6.92B	-18.70	-68.70%	―	-100.00%	53.89%
BCRX	55 Neutral	$1.57B	―	―	―	45.38%	92.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRPT	49 Neutral	$2.34B	-7.31	-21.37%	―	47.15%	-311.26%
CLDX	41 Neutral	$1.77B	-7.62	-32.44%	―	-73.94%	-31.70%

BioCryst Corporate Events

BioCryst Gains FDA Approval for Pediatric HAE Drug

On December 12, 2025, BioCryst Pharmaceuticals announced the FDA approval of its new drug application for an oral pellet formulation of ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to less than 12 years. This approval marks a significant milestone as it introduces the first and only oral prophylactic treatment for this age group, offering a more convenient administration method compared to previous intravenous or subcutaneous options. The approval was supported by positive interim data from the APeX-P clinical trial, which demonstrated early and sustained reductions in monthly attack rates. The new formulation aims to alleviate the treatment burden for young patients and their caregivers, potentially transforming the management of HAE in children.

BioCryst Announces Board Chair Transition Plan

On December 9, 2025, Nancy J. Hutson, Ph.D. announced her intention to retire from BioCryst Pharmaceuticals’ Board of Directors, effective by the earlier of the company’s 2026 annual meeting or the closing of its proposed acquisition of Astria Therapeutics. Dr. Hutson, who has served as Chair of the Board and various committees, cited no disagreements with the company. In response, the Board elected Vincent J. Milano as the next Chair, effective upon her retirement.

BioCryst Announces Early Termination for Astria Merger

On December 3, 2025, BioCryst Pharmaceuticals announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics. This development satisfies one of the conditions for the merger, which is expected to close in the first quarter of 2026, pending other customary closing conditions. The merger is anticipated to enhance BioCryst’s market position, although it carries risks such as potential integration challenges and financial implications.

BioCryst Reports Q3 2025 Financial Growth and Strategy

In the third quarter of 2025, BioCryst Pharmaceuticals reported significant financial growth, with ORLADEYO net revenue reaching $159.1 million, a 37% increase year-over-year. The company completed the sale of its European ORLADEYO business, using proceeds to retire Pharmakon term debt, and announced a definitive agreement to acquire Astria Therapeutics, expected to close in the first quarter of 2026. These strategic moves are expected to enhance BioCryst’s market position and financial stability, with the company raising its full-year revenue guidance and lowering its operating expense outlook for 2025.

BioCryst Announces Merger with Astria Therapeutics

On October 14, 2025, BioCryst Pharmaceuticals announced a merger agreement with Astria Therapeutics, which will see Astria become a wholly owned subsidiary of BioCryst. The merger, expected to close in the first quarter of 2026, involves an exchange of shares and cash, with Astria’s stock to be delisted from Nasdaq. The merger aims to enhance BioCryst’s market position and operational capabilities, with financing commitments secured from Blackstone to support the transaction. The merger agreement includes various conditions and provisions, such as stockholder approval and regulatory clearances, with potential termination fees if the agreement is not fulfilled.

BioCryst Sells European ORLADEYO Business for $250M

On October 1, 2025, BioCryst Pharmaceuticals completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with potential future milestones of up to $14 million. This transaction allows BioCryst to focus on its U.S. operations, improve its operating margin, and retire a significant portion of its debt, positioning the company for future strategic activities. Neopharmed Gentili will handle the commercialization of ORLADEYO in Europe, ensuring continuity for the brand and patients.